Asymchem Laboratories Tianjin CoASLTY 72 PE Ratio without NRI is 26.00 as of Jun. 24, 2026, which is 40% below its 10-year median of 42.98. GuruFocus rates ASLTY with a GF Score™ of 72/100 and a GF Value™ of $4.52 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 267 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks worse than 68.54% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-24), Asymchem Laboratories Tianjin Co's share price is $6.37.
Asymchem Laboratories Tianjin Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25. Therefore, Asymchem Laboratories Tianjin Co's PE Ratio without NRI for today is 26.00.
During the past 13 years, Asymchem Laboratories Tianjin Co's highest PE Ratio without NRI was 127.13. The lowest was 12.36. And the median was 42.98.
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Asymchem Laboratories Tianjin Co PE Ratio without NRI Related Terms
Asymchem Laboratories Tianjin Co PE Ratio without NRI Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co PE Ratio without NRI Chart
ASLTY vs VRTX, REGN, ALNY: PE Ratio without NRI Comparison
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's PE Ratio without NRI falls into.
Asymchem Laboratories Tianjin Co PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Asymchem Laboratories Tianjin Co's Share Price of today is $6.37.
Asymchem Laboratories Tianjin Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Asymchem Laboratories Tianjin Co (ASLTY) has a PE Ratio without NRI of 26.00 as of Jun. 24, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 40% below median its historical median of 42.98. Over the past decade, Asymchem Laboratories Tianjin Co's PE Ratio without NRI has ranged from 12.36 to 127.13. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #183 out of 267 companies in the Biotechnology industry, placing it in the top 68.5%.
Is Asymchem Laboratories Tianjin Co's PE Ratio without NRI too high?
Asymchem Laboratories Tianjin Co's current PE Ratio without NRI of 26.00 is 40% below median its 10-year median of 42.98. Over the past 10 years, this metric has ranged from a low of 12.36 to a high of 127.13. The Biotechnology industry median PE Ratio without NRI is 25.27. Asymchem Laboratories Tianjin Co's value of 26.00 is 2.9% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #183 out of 267 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's PE Ratio without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #183 out of 267 companies for PE Ratio without NRI. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median PE Ratio without NRI is 25.27. Asymchem Laboratories Tianjin Co's value of 26.00 is 2.9% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own PE Ratio without NRI has ranged from 12.36 to 127.13 over the past decade. While the company's 10-year median is 42.98 vs. the industry median of 25.27, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Biotechnology company?
The median PE Ratio without NRI among Biotechnology companies is 25.27, based on 267 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current PE Ratio without NRI of 26.00 is 2.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median PE Ratio without NRI is 25.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current PE Ratio without NRI is 26.00, which is 40% below median its own 10-year median of 42.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.52, compared to a current price of $6.37 — trading 40.9% above its estimated fair value. The current PE Ratio without NRI is 26.00, which is 40% below median its 10-year median of 42.98 and 2.9% above the Biotechnology industry median of 25.27. Asymchem Laboratories Tianjin Co's overall GF Score™ is 72/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current PE Ratio without NRI is 26.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $6.37 is trading 40.9% above its estimated GF Value™ of $4.52.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
PE Ratio without NRI: 26.00 (40% below median its 10-year median of 42.98)
GF Value™: $4.52 vs. price of $6.37 (40.9% above fair value)
Industry Position: 2.9% above the Biotechnology median (#183 of 267)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Business Description
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
72GF Score
Get the complete analysis for ASLTY
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
